CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 71 enrolled
Drug / intervention
Performance of WHEELS-I in promoting DASH/SRD adoptionbehavioral
Likely dose
Not stated in record
Key inclusion· 4
  • Veteran aged 45 years or older
  • Hypertension defined as screening systolic BP ≥130 and/or diastolic BP ≥85 mmHg, or currently taking antihypertensive medications
  • Metabolic syndrome with BMI ≥30 kg/m² and/or waist circumference >94 cm
  • Willing to participate in WHEELS-I program using smartphone application or email
Key exclusion· 16
  • On-treatment systolic BP >160 mmHg at screening visit
  • Previous history of heart failure
  • Left ventricular ejection fraction <50%
  • Moderate or severe valvular heart disease

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03170375
NCT03170375N/ACompleted

Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome

VA Office of Research and Development·interventional·Posted May 31, 2017·Updated Sep 10, 2025

In Brief

A clinical study evaluating Performance of WHEELS-I in promoting DASH/SRD adoption for Heart Failure. Completed, enrolled 71 participants across 1 site.

Detailed Summary

Tens of thousands of Veterans have heart failure with preserved ejection fraction (HFpEF), and suffer poor quality of life, frequent hospitalizations, and high death rates. Older Veterans and those with high blood pressure, obesity, and the metabolic syndrome (abnormal cholesterol and resistance to insulin's effects) are particularly at risk for HFpEF. However, it is not clear why only some Veterans in this risk group eventually develop HFpEF. Extensive information from experimental animal models and some human studies suggests that dietary patterns in vulnerable 'salt-sensitive' people could contribute to the risk for HFpEF. Reducing salt intake and increasing overall dietary quality in at-risk Veterans could prevent heart and blood vessel damage that ultimately leads to HFpEF. Reducing the development of HFpEF, which currently has no definitive treatment, is highly relevant to the VA's mission to emphasize prevention of disease and population health.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedMay 31, 2017
Enrollment StartJan 2, 2019
Primary CompletionMar 31, 2024
Study CompletionJan 23, 2025
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 9.1 years ago

Interventions

Performance of WHEELS-I in promoting DASH/SRD adoptionbehavioral

All participants will receive motivational interviewing (MI) based counseling. Participants in the MI + WHEELS-I arm will also receive the WHEELS-I electronically-delivered tailored messaging.